SEC Form 4 · accession 0001209191-19-000813
REATA PHARMACEUTICALS INC · RETA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael D Wortley
Officer — Chief Legal Officer
Period of report
Jan 2, 2019
Accepted (ET)
Jan 3, 2019 · 2:53 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358762
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1,F2 | $55.73 | Jan 2, 2019 | A | 34,500 | A | — | Jan 2, 2029 | Class B common stock | 34,500 | 34,500 | D |
Explanation of responses
- F1The options vest in sixteen equal quarterly installments beginning on April 2, 2019, subject to continued service through each vesting date.
- F2The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date.